Johnson & Johnson news - the latest news from Labiotech.eu

Seven pharma companies form alliance to prepare for future pandemics

Jim Cornall — Thu, 20 Jul 2023 14:00:00 +0000

Seven pharmaceutical companies have established the INTREPID Alliance with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics. The seven companies are AbbVie, Amgen, Gilead, Johnson & Johnson, Novartis, Roche and Takeda. The INTREPID alliance creation is in support of the 100 Days Mission, which seeks to have […]

The post Seven pharma companies form alliance to prepare for future pandemics appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Shasqi using click chemistry to target cancer

Jim Cornall — Tue, 06 Jun 2023 06:23:53 +0000

Shasqi, Inc., whose mission is to revolutionize cancer treatment with click chemistry, has entered into a research collaboration with Johnson & Johnson Enterprise Innovation Inc. Through the collaboration, Shasqi will apply its tumor-targeted Click Activated Protodrugs Against Cancer (CAPAC) platform to the development of new cancer therapies. Shasqi’s CAPAC platform relies on chemistry, not biology, […]

The post Shasqi using click chemistry to target cancer appeared first on Labiotech.eu.

Cell and gene therapies gain momentum in Basel

External Contributor — Tue, 17 Jan 2023 10:52:06 +0000

Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the globe, and a growing number are choosing the Swiss city of Basel as their base. These companies are taking advantage of the talent pool, academic institutions and investors that the area has to offer, culturing […]

The post Cell and gene therapies gain momentum in Basel appeared first on Labiotech.eu.

LIfT BioSciences gets a double boost

Jim Cornall — Mon, 19 Dec 2022 13:13:07 +0000

LIfT BioSciences’ is receiving more investment, and has been accepted into Johnson & Johnson Innovation’s JLABS network. LIfT BioSciences’ lead investor, Starbloom Capital, provided further investment into the company to accelerate LIfT’s R&D plans and progress N-LIfT, the company’s first-to-market anti-cancer innate cell therapy, (neutrophil only leukocyte infusion therapy) into clinical development by Q1 2024, […]

The post LIfT BioSciences gets a double boost appeared first on Labiotech.eu.

ASPIRE set up to collaborate on amyloidosis

Jim Cornall — Tue, 04 Oct 2022 14:45:17 +0000

A new group of biotech and pharma companies has been assembled by the Amyloidosis Research Consortium (ARC). ASPIRE (amyloidosis stakeholder partnerships for impact reach and equity), is a collaboration between biotech and pharmaceutical companies committed to advancing solutions, improving diagnosis and systems of care, and addressing obstacles to health equity on behalf of amyloidosis patients. […]

The post ASPIRE set up to collaborate on amyloidosis appeared first on Labiotech.eu.

Hope for children with chronic graft versus host disease as Johnson & Johnson drug approved

Liza Laws — Thu, 25 Aug 2022 14:37:30 +0000

A treatment for chronic graft versus host disease in children aged one year and older has been approved by the U.S. Food and Drug Administration (FDA). Graft versus host disease is a common complication after receiving a donor stem-cell or bone marrow transplantation. Sometimes, the graft doesn’t recognize the host as being friendly and sees the […]

The post Hope for children with chronic graft versus host disease as Johnson & Johnson drug approved appeared first on Labiotech.eu.

Yumanity selling neurology assets and merging with Kineta

Jim Cornall — Tue, 07 Jun 2022 15:08:41 +0000

U.S. biopharma company Yumanity Therapeutics, Inc. is selling off its lead clinical-stage neurodegenerative product candidate YTX-7739 to Janssen Pharmaceutica NV, and also entering a merger with Kineta, Inc. YTX-7739, as well as Yumanity’s discovery-stage neuroscience product candidates and targets are being sold to Janssen, part of the Janssen Pharmaceutical Companies of Johnson & Johnson, for […]

The post Yumanity selling neurology assets and merging with Kineta appeared first on Labiotech.eu.

As J&J Vaccine Fails Phase II, the Quest for an HIV Vaccine Continues

Helen Albert — Wed, 08 Sep 2021 10:41:10 +0000

Johnson & Johnson became the latest company to have a failed vaccine trial against HIV last week. While it was a great disappointment to many, efforts continue in this space, helped by recent Covid-19 vaccine advances. HIV has been around for decades. While antiretroviral treatments have improved enormously, turning what was once a death sentence […]

The post As J&J Vaccine Fails Phase II, the Quest for an HIV Vaccine Continues appeared first on Labiotech.eu.

EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls

Jonathan Smith — Tue, 27 Apr 2021 10:20:40 +0000

While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations centered mostly on improving existing approaches. Which areas of multiple sclerosis treatment need more options? At the end of March, the EMA made key decisions on three treatments for multiple sclerosis (MS), a chronic neurodegenerative disease affecting 2.5 million people […]

The post EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls appeared first on Labiotech.eu.

This Incubator Knows How to Get Biotechs Started

External Contributor — Mon, 10 Dec 2018 09:00:21 +0000

When it comes to drug discovery and development, nowadays a lot of the work is done by small- or medium-sized healthcare companies. The biopharma industry heavily relies on their results, so SMEs carry an immense load on their shoulders. But without outside help, their mission is nearly impossible. In the healthcare industry, a brilliant idea […]

The post This Incubator Knows How to Get Biotechs Started appeared first on Labiotech.eu.

Check Out Europe’s Hottest Pitching Event for Startups!

External Contributor — Wed, 05 Sep 2018 08:00:18 +0000

Last year Berlin, this year Copenhagen – No matter where in Europe, this is the best opportunity to meet the most inspiring biotech startups out there: The Startup Slam at BIO-Europe 2018! APPLY TO PITCH YOUR COMPANY A pitching competition like no other, the Startup Slam allows entrepreneurs from all over Europe to present their […]

The post Check Out Europe’s Hottest Pitching Event for Startups! appeared first on Labiotech.eu.

The Startup Slam at BIO-Europe 2017! Choosing the Winner was Hard!

External Contributor — Wed, 13 Dec 2017 09:00:06 +0000

What would a large event like BIO-Europe be without startups? They’re not only the life and soul of any evening networking reception, but also an essential and indispensable part of the life sciences community. Johnson & Johnson Innovation, together with EBD Group, has picked up on that thought and presented the Startup Slam at BIO-Europe. This year’s […]

The post The Startup Slam at BIO-Europe 2017! Choosing the Winner was Hard! appeared first on Labiotech.eu.

UK-based VC Launches Massive $300M Fund to Fill Gap for Late-Stage Biotech

Melanie De Almeida — Thu, 15 Jun 2017 10:22:28 +0000

The UK-based VC Medicxi has raised a massive $300M (€268M) fund backed by Novartis and Google’s Verily to invest in late-stage drug development. After the former life science branch of famous Index Ventures went solo in 2016 and became Medicxi, the VC was able to raise a huge sum of €210M in its first round to support early-stage, single-asset […]

The post UK-based VC Launches Massive $300M Fund to Fill Gap for Late-Stage Biotech appeared first on Labiotech.eu.

Which European Blockbusters Topped the Charts in 2016?

Melanie De Almeida — Wed, 08 Mar 2017 12:48:57 +0000

Blockbuster drugs are raking in billions each year in sales. Let’s have a look at the top 7 European best-seller drugs of 2016 and what their competition has to say. Not surprisingly, the top 3 best-selling drugs in Europe are biologicals, which are revolutionizing the treatment possibilities for a range of conditions, from cancer to chronic diseases. But with the increasing […]

The post Which European Blockbusters Topped the Charts in 2016? appeared first on Labiotech.eu.

Actelion’s key Drug linked to Deaths, prompting EMA Investigation

Melanie De Almeida — Wed, 15 Feb 2017 11:43:03 +0000

Johnson & Johnson is certainly counting on its recent acquisition of the European biotech success Actelion to upgrade its top line. Now Actelion’s key product, Uptravi, may be facing some safety issues. One of Actelion’s new products, Uptravi, was launched last January against pulmonary arterial hypertension (PAH) and – with a €150000 ($160,000) price tag – it makes up a […]

The post Actelion’s key Drug linked to Deaths, prompting EMA Investigation appeared first on Labiotech.eu.

Europe’s Largest Biotech Actelion Seals the Deal with J&J for €28B

Evelyn Warner — Thu, 26 Jan 2017 07:30:35 +0000

Actelion will be acquired by J&J for a whopping €27.9B, and its early R&D pipeline will be spun out into a new Switzerland-based outfit. The wait is over folks: Actelion, the largest biotech in Europe and one of the only 9 to make it to the billion-euro club in 2016, has just announced its acquisition by Johnson & Johnson for a […]

The post Europe’s Largest Biotech Actelion Seals the Deal with J&J for €28B appeared first on Labiotech.eu.

UPDATE: J&J and Actelion settle on a price, R&D assets will be spun out

Clara Rodríguez Fernández — Fri, 13 Jan 2017 08:30:09 +0000

UPDATE (12/01/2017): J&J and Actelion have reportedly settled on a price: $260 (€245) per share, totaling more than $28 (€26) billion. The Swiss biotech’s R&D assets will be spun out into a new company that will remain independent. UPDATE (03/01/2017): The deal has veered towards splitting Actelion into two companies, one for its commercialized portfolio […]

The post UPDATE: J&J and Actelion settle on a price, R&D assets will be spun out appeared first on Labiotech.eu.

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Clara Rodríguez Fernández — Mon, 26 Dec 2016 07:00:06 +0000

Curious about which technologies have attracted the most cash in biotech finance this year? Here’s a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016 has been the worst year for biotech finance in a decade. The political scene has become unfavorable for British biotech after Brexit, and the uncertainty raised by […]

The post The Largest Deals, Fundraising and Exits of 2016 in European Biotech appeared first on Labiotech.eu.

Results from 45% of Clinical Trials are kept Secret

Clara Rodríguez Fernández — Mon, 07 Nov 2016 12:27:41 +0000

A new transparency study has identified Sanofi, Novartis and GSK as the companies that keep the most clinical trial results unreported. TrialsTracker is a tool developed at the University of Oxford that automatically rates transparency on clinical trials by checking if there are results available in clinicaltrials.gov and PubMed. The results: globally, 45% of data on […]

The post Results from 45% of Clinical Trials are kept Secret appeared first on Labiotech.eu.

New Psoriasis Antibody Therapy puts pressure on Best-Seller drug Humira

Clara Rodríguez Fernández — Wed, 05 Oct 2016 06:00:13 +0000

New results from a Phase III trial show that guselkumab, an antibody therapy for the autoimmune disease plaque psoriasis, is performing better than the number one best-seller drug Humira (adalimumab) from AbbVie. The new drug is expected to be commercially available as early as 2018. Since MorphoSys licensed guselkumab to Janssen Biotech, in 2007, the drug has been performing […]

The post New Psoriasis Antibody Therapy puts pressure on Best-Seller drug Humira appeared first on Labiotech.eu.